Wellington Management Group LLP Trims Holdings in Elanco Animal Health Incorporated $ELAN

Wellington Management Group LLP decreased its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 11.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,676,050 shares of the company’s stock after selling 359,806 shares during the period. Wellington Management Group LLP’s holdings in Elanco Animal Health were worth $65,858,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Elanco Animal Health in the 1st quarter worth $2,065,000. Goldman Sachs Group Inc. lifted its position in shares of Elanco Animal Health by 104.5% in the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after acquiring an additional 2,445,872 shares in the last quarter. Empowered Funds LLC boosted its stake in shares of Elanco Animal Health by 35.2% in the first quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock worth $166,000 after acquiring an additional 4,121 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Elanco Animal Health by 4.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock worth $18,830,000 after purchasing an additional 76,408 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its position in shares of Elanco Animal Health by 2,006.9% during the second quarter. Arrowstreet Capital Limited Partnership now owns 310,383 shares of the company’s stock worth $4,432,000 after purchasing an additional 295,651 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently commented on ELAN. Piper Sandler reissued an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. UBS Group boosted their target price on shares of Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Citigroup upped their target price on shares of Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Weiss Ratings cut shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research note on Thursday, August 20th. Finally, Wall Street Zen lowered Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 24th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Elanco Animal Health has an average rating of “Moderate Buy” and a consensus target price of $29.09.

Elanco Animal Health Stock Up 2.8%

Shares of ELAN opened at $24.59 on Thursday. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58. The business has a fifty day moving average of $24.65 and a 200 day moving average of $23.98. The company has a market cap of $12.29 billion, a PE ratio of -59.98, a P/E/G ratio of 1.78 and a beta of 1.68. Elanco Animal Health Incorporated has a 52-week low of $17.11 and a 52-week high of $27.98.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.07. The business had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, sell-side analysts expect that Elanco Animal Health Incorporated will post 1.12 EPS for the current year.

Insider Activity at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Erik Kurzius bought 40,000 shares of the company’s stock in a transaction on Thursday, August 20th. The stock was acquired at an average price of $23.40 per share, for a total transaction of $936,000.00. Following the completion of the transaction, the director directly owned 188,647 shares of the company’s stock, valued at approximately $4,414,339.80. This represents a 26.91% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Shiv O’neill bought 3,998 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were acquired at an average cost of $23.58 per share, for a total transaction of $94,272.84. Following the purchase, the insider owned 87,832 shares of the company’s stock, valued at approximately $2,071,078.56. The trade was a 4.77% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 63,198 shares of company stock worth $1,473,109 in the last three months. 1.14% of the stock is owned by insiders.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.